Let cost effectiveness models be open to scrutinyBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39360.379664.BE (Published 11 October 2007) Cite this as: BMJ 2007;335:735
- Chris Poole, director1,
- Samir Agrawal, consultant haematologist2,
- Craig J Currie, honorary senior research fellow3
- 1Pharmatelligence LLP, Cardiff MediCentre, Cardiff
- 2Department of Haematological Oncology, St Bartholomew's Hospital, London
- 3Department of Medicine, Cardiff University, Cardiff
In light of the recent ruling over the National Institute for Health and Clinical Excellence's (NICE) decision on donezepil,1 2 we wish to comment on the adversarial system of drug evaluation and the inadequacy of NICE providing read-only versions of cost effectiveness models for the purposes of reviewing their decisions.
The assertion that “[NICE] is not in a position to deal with the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial